OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Advances is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Complement C5 Inhibition in early onset HELLP Syndrome	173
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	169
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	141
Transfusion therapy for sickle cell disease: what’s new?	132
Complete absence of GLUT1 does not impair human terminal erythroid differentiation	125
Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library	123
Steroid tapering after GVHD Rx: not too fast, not too slow	114
Megakaryocyte/platelet-derived TGF-β1 inhibits megakaryopoiesis in bone marrow by regulating thrombopoietin production in liver	106
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A	105
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study	99
Genome-wide whole-blood transcriptome profiling across inherited bone marrow failure subtypes	98
LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling	98
Addressing and overcoming disparities in GVHD	92
COVID-19 vaccination during therapy in relation to COVID-19 death in CLL	91
Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report	89
Pediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children	89
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia	88
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection	87
On a collision course: SARS-CoV-2 variants and CAR T cells	86
Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors	85
International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies	83
Long term outcome of Hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse	83
Pirillo C, Birch F, Tissot FS, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv. 2022;6(10):3126-3141.	79
Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia	79
Campbell BA, Dobos G, Haider Z, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood Adv. 2023;7(21):	79

Kennedy VE, Wong C, Huang C-Y, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021;5(23):5344-5348.	77
Glucagon-Like Peptide 1 Receptor Agonists and Venous Thromboembolism in Type 2 Diabetes: A Target Trial Emulation	76
Impact of Vein-to-vein Time in Patients With R/R LBCL Treated With Axicabtagene Ciloleucel	75
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia	75
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry	75
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	74
Prognostic role of interim PET in patients with follicular lymphoma: a post-hoc study of FOLL12 trial by FIL	74
Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL	73
Desensitization to calaspargase pegol appears to be less successful than pegaspargase	73
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses	72
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool	71
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia	71
Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children	65
Mitigating T-Cell Mitochondrial Dysfunction in CLL to Augment CAR T-Cell Therapy: Evaluation in an Immunocompetent Model	65
Best but not perfect: indirect measure of low iron stores	65
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization	65
Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia	63
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea	62
BCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes	61
Plasma and rhADAMTS13 reduce trauma-induced organ failure by restoring the ADAMTS13-VWF axis	61
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in lymphoma patients	59
Long term follow-up of MRD guided treatment of Ibrutinib plus Venetoclax for Relapsed CLL: phase 2 VISION/HO141 trial	59
A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival	59
Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network	58
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years	58
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies	57
Applying CRISPR-Cas9 screens to dissect hematological malignancies	57
Structural analysis of platelet fragments and extracellular vesicles produced by apheresis platelets during storage	56
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia	54
ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV	54
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes	54
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma	54
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium	54